Back

Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Heart failure red flags and their management Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Thibaud Damy

University Hospital Henri Mondor, Creteil (France)

5 More presentations in this session

Presentation thumbnail
Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis
Mr A. Ji (San Francisco, US)
Abstract Slides Video
Presentation thumbnail
The use of 99mTc-PYP SPECT/CT in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin cardiomyopathy
Doctor A. Yu (Hsinchu, TW)
Abstract Slides Video
Presentation thumbnail
The role of infliximab in treating refractory cardiac sarcoidosis
Doctor R. Ahmed (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
Survival analysis of tafamidis use in patients with ATTR cardiac amyloidosis
Doctor N. Starr (Co. Limerick, IE)
Abstract Slides Video
Presentation thumbnail
Non-adherence to prescribed medications in ambulatory patients with heart failure assessed using liquid chromatography tandem mass spectrometry
Doctor S. Sze (Leicester, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure red flags and their management

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources